Research and Markets has announced the addition of the "Research Report on China''s Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017" report to their offering.
Benign prostatic hyperplasia (BPH) is a common disease among middle-aged and elderly men, with an increasing morbidity as the rise in ages. Its invasion is possibly related to race and regions.
In China, the PH morbidity of men in urban regions is far higher than that in rural regions. The PH morbidity is influenced by several factors: the morbidity of married people higher than that of unmarried ones and the relatively high morbidity among patients suffering from diseases in the nervous system, respiratory system and reproductive system. The morbidity of people with a family history of PH is over 50%.
Only under severe symptoms will PH patients need the surgical treatment. In most cases, the long-term drug treatment is adopted. Currently, the common clinical drugs include receptor blocking agents, antiandrogen drugs, traditional Chinese medicine preparations, plant preparations, etc.
In 2012, the market size of China''s hospital-use anti-PH drugs reached CNY 3.67 billion, increasing by 12.6% YOY.
Four drug varieties, namely, Finasteride, Tamsulosin, Doxazosin and Cernilton dominate China''s hospital-use anti-PH drug market. In 2011, it controlled nearly 80% of hospital-use anti-PH drug market nationwide.
In the coming years, a large group of branded drugs will successively lose patent protection, which is a great opportunity for non-patent drug manufacturers. Meanwhile, it is also a huge market. Therefore, the prospect of China''s anti-PH drug market is very bright. The annual growth rate of China''s anti-PH drug market size is predicted to be over 10% in years to come.
More following information can be acquired through this report:
– Current R&D Status of Anti-PH Drugs
– Competition in China''s Anti-PH Drug Market
– Market Sizes of China''s Major Anti-PH Drugs
– Prediction on Development of China''s Anti-PH Drugs
Following people are recommended to buy this report:
– Anti-PH Drug Manufacturers
– Pharmaceutical Agents/Hospitals
– Investors and Research Institutions Focusing on Anti-PH Drugs
